We have previously reported that the cytotoxic activity of murine CD8 + CTLs specific for HIV-1 gp160 envelope protein was markedly inhibited in vitro by brief exposure to a free epitope peptide P18-I10 (aa: RGPGRAFVTI) using the epitope-specific CTL line (LINE-IIIB) or a clone (RT-1). We have also shown that recently stimulated P18-I10-specific murine CTLs rapidly fell into apoptosis in vitro after brief exposure to the free epitope peptide. In the present study, we examined whether similar inactivation or apoptosis of recently stimulated CTLs occurred in vivo by exposure to the free epitope peptide using TCR transgenic (Tg-RT-1) mice expressing TCRαβ genes of CTL clone RT-1. When the Tg mice were inoculated with recombinant vaccinia virus expressing HIV-1-IIIB gp160 genes followed by injection of P18-I10 epitope peptide, apparent reduction in the number of CTLs determined by flow cytometry using H-2D 
Introduction

CD8
+ CTLs recognize virus-derived processed peptides in association with class I MHC molecules presented by antigen-presenting cells (APCs) as well as virus-infected cells, and directly eradicate them. Such CTLs also secrete various antiviral soluble factors, such as MIP-1β and RANTES, that block HIV-1 entry through chemokine receptors (1, 2); therefore, it has been widely accepted that these antigen-specific CD8 + CTLs play a central role in preventing the spread of various viruses, including HIV-1, in the initial phase of infection.
However, recent studies have demonstrated that in vivo exposure to high doses of viruses or their components causes inactivation or deletion of antigen-specific CD8 + CTLs (3) (4) (5) . Indeed, Gallimore et al. showed in a mouse model that noncytopathic lymphocytic choriomeningitis virus (LCMV) infection was not completely cleared when mice were infected with high doses of LCMV, and very high titers of virus were detected in LCMV-infected cells and, at that time, the number of virus-specific CTLs was markedly reduced in both the spleen and thymus, although LCMV-specific CD8 + CTLs were rapidly elicited from the hosts with low doses of infection (3) . Moreover, in chronically infected mice, they failed to control an infection that might be caused by prolonged activation of virus-specific CD8 + T cells showing declined capacity to produce various cytokines, such as IL-2, TNF-α and IFN-γ (5). Furthermore, high viral loads were associated not only with the ablation of CD8 + T cell responses but also with the impaired production of IL-2 by virus-specific CD4 + T cells (4) . Consequently, functional inactivation of virus-specific CD8 + T cells was observed in the absence of CD4 + T-cell help. Similarly, it has been reported that significant numbers of HIV-1-specific T-cell clones involved in the immune responses rapidly disappeared in patients with primary HIV-1 infection (6) . Moreover, HIV-1-specific CTLs appeared to be eliminated in the course of disease progression (7); however, this phenomenon, called clonal exhaustion, and other mechanisms by which CTLs are deleted are poorly understood.
We have previously reported that cytotoxic activity of CD8 + CTLs specific to HIV-1 envelope gp160 was markedly inhibited in vitro by brief exposure to a free epitope peptide identified from the V3-region of HIV-1 gp160, P18-I10 (aa: RGPGRAFVTI) using its specific murine CTL line (LINE-IIIB) and clone (RT-1) (8) . We have also shown that such P18-I10-specific murine CD8 + CTLs rapidly fell into apoptosis in vitro after brief exposure to the free epitopic peptide P18-I10 when recently stimulated (9) . In this system, the rapid onset of apoptosis was induced predominantly on activated CTLs, which recognized foreign antigens as processed peptides in association with class I MHC molecules on the cell surface of their own or other cells via specific TCRs.
Recently, similar rapid death of CD8 + CTLs was reported. Alexander-Miller et al. reported that when high-avidity CTLs having strong cytolytic activity were stimulated by APCs with low doses of peptide-MHC at supraoptimal densities, apparent apoptosis of CD8 + CTLs was observed (10) (11) (12) . Also, Contini et al. and Cebecauer et al. reported that when cloned CTL lines were treated with soluble MHC-peptide complexes, Fas-dependent apoptosis or Fas-independent programmed necrosis was induced, respectively (13, 14) ; however, these studies were performed in vitro using antigen-specific CTL lines or clones, and the actual features of virus-specific CD8 + CTL apoptosis with viral components have not been demonstrated in vivo.
In the present study, we attempted to perform experiments to see whether similar inactivation or apoptosis of CD8 + CTLs might occur in vivo using Tg-RT-1 mice (15) expressing both α and β TCR genes of clone RT-1 specific to P18-I10 (16) . When mice were inoculated with recombinant vaccinia virus expressing HIV-1-IIIB gp160 genes (vSC25) (17) followed by the injection of free epitope P18-I10 a few days later, marked reduction in the percentage of CTLs was observed, probably mediated through apoptosis, as determined not only by flow cytometric analysis using H-2D d /P18-I10 pentamer but also by microscopic analysis. Moreover, we demonstrated here that we could prevent apoptosis by pretreatment with immunosuppressive agents, such as cyclosporin A (CsA) and tacrolimus (formerly known as FK506).
Analysis of the precise mechanisms of the phenomenon and the development of procedures for preventing apoptosis of activated antigen-specific CD8 + CTLs in vivo will provide a new strategy to control various virus infections by maintaining a CTL-based immune-surveillance system particularly in the initial phase of infection.
Methods
Mice
Tg-RT-1 mice expressing genes of TCRα and TCRβ chains (Vα 42H11 and Vβ8.1) of a murine CTL clone RT-1 (16) specific to P18-I10 (RGPGRAFVTI) restricted by class I MHC molecule (17, 18) , carrying the genetic background of BALB/c (H-2D d ), were established and bred in our colony (15) . The expression of TCRαβ chain-specific DNA in tails was analyzed by PCR using specific primers. Briefly, genomic DNA from the tail of Tg mice was amplified with P18-I10-specific primers: (5ʹ-GGCACTCTGCTTTCTGTCAA-3ʹ) and (5ʹ-CAG GAGGATTCGGAGTC-3ʹ) for TCRα chain, and (5ʹ-CTGAGCA GTTCTTCGGACCA-3ʹ) and (5ʹ-CAAGAACGGCTCAGGATG CAT-3ʹ) for TCRβ chain. The resulting PCR products were separated by agarose gel electrophoresis for determining TCR expression. For experiments, F1 mice of Tg-RT-1 and BALB/c mice were used. All mice used in this study were maintained in a specific pathogen-free microisolator environment. All experiments were performed according to the guidelines of the NIH Guide for the Care and Use of Laboratory Animals.
Recombinant vaccinia virus
vSC25 has been described (17) and used for immunizing mice to induce envelope-specific CTLs. For infection experiments, mice were intraperitoneally (i.p.) inoculated with 1 ×10
7 PFU per mouse of vSC25. Uninfected control mice were injected with the same volume of PBS.
Synthetic peptides and reagents
Peptides used in this study were all purchased from Takara Bio Co. (Tokyo, Japan). Peptide P18-I10 represents the immunodominant CTL epitope presented by the murine class I MHC molecule H-2D d in the V3 loop of HIV-1 gp160 glycoprotein found in strain IIIB (17, 18) . Epitopic analog peptide I-10(325I) (aa: RGPGRAFITI) (19) , control peptides RF-10 (aa: KGPGRVIYAT) and MNT10 (aa: IGPGRAFYTT), the same immunodominant site in gp160 of another strain RF and MN of HIV-1, respectively (20) , were also used. CsA (from Tolypocladium inflatum) was purchased from Sigma-Aldrich (St Louis, MO, USA). CsA was dissolved in ethanol (20 mg ml −1 ) and then diluted with 30% ethanol in distilled water. Tacrolimus (a gift from Fujisawa Pharmaceutical, Tokyo, Japan) was dissolved in ethanol (5 mg ml −1 ) and then diluted with 30% ethanol in distilled water. 
Cell lines and in vitro CTL
Flow cytometric analysis
Flow cytometric analysis was performed to determine the surface molecule expression of the cells using a FACScan analyzer (Becton Dickinson Immunochemical Systems, Mountain View, CA, USA). Half a million cells were pelleted and resuspended in 100 µl PBS containing 1% FCS and 0.1% sodium azide. FITC-labeled or PE-labeled mAbs were added to the pellet and incubated for 30 min at 4°C. Cells were then washed twice and resuspended in the same PBS. The following mAbs were used: FITC-labeled 
Cytotoxicity assay
Cytolytic activity of CTLs was measured as previously described (17) using a standard 4 h 51 Cr-release assay. Bystander killing during CTL-mediated cytolysis was assessed by the procedure as described previously (22) . In brief, 5 × 10 3 of
51
Cr-labeled target cells (Neo) were incubated with CTLs and various numbers of antigen-expressing cells or nonexpressing cells (Neo) in 96-well round-bottom plates for 6 h at 37°C. After incubation, 100 µl of the supernatants were collected to measure the amount of released 51 Cr radioactivity with a Packard Auto-Gamma 5650 counter (Hewlett-Packard, Japan). Maximum release was determined from the supernatant of cells that had been lysed by the addition of 5% Triton X-100, and spontaneous release was determined from target cells incubated without added effector cells. The percentage of specific lysis was calculated as 100 × (experimental release − spontaneous release)/(maximum release − spontaneous release).
Detection of DNA fragmentation
DNA fragmentation was detected as previously described (9) . Briefly, the cells were lysed with hypotonic lysing buffer (10 mM Tris, 10 mM EDTA and 0.5% Triton X-100, pH 7.4) at 4°C for 10 min and centrifuged at 20 400 × g for 10 min to remove unfragmented DNA and cell debris. RNase A (200 µg ml −1 ) and proteinase K (200 µg ml −1 ) were added to samples, and fragmented DNA was recovered by centrifugation after precipitation overnight at −20°C in isopropanol (1 v) in the presence of 0.5 M NaCl. Electrophoresis was conducted on 2% agarose gels in 40 mM Tris-acetate buffer (pH 8.0) containing 1 mM EDTA, and DNA was visualized by ethidium bromide staining.
Detection of apoptosis
CTL apoptosis was detected with the Annexin V-FITC Apoptosis Detection Kit (BioVision Research Products, Mountain View, CA, USA) according to the manufacturer's instructions.
Histochemical studies and electron microscopic analyses
Dead cells in tissues were analyzed by toluidine blue staining as well as electron microscopy. Tissue samples were fixed in 2.5% glutaraldehyde overnight. Following fixation for 2 h at 4°C in 1% osmium tetroxide, they were dehydrated using gradually increasing concentrations of ethanol and embedded into Epon resin 812 (TAAB, Aldermaston UK). Sections were incubated with 0.1% toluidine blue solution at room temperature and observed with a Nikon UFX-IIA (Nikon, Tokyo, Japan). For electron microscopic analysis, sections of 100-nm thickness were cut using an Ultracut E ultramicrotome; grids were then counterstained with 2% uranyl acetate and 1% lead citrate and imaged using a Hitachi H7100 electron microscope (Hitachi, Tokyo, Japan).
Statistical analysis
The results were analyzed using Student's t-test and the results are presented as the mean value ± SD. Differences at P < 0.05 were considered significant.
Results
Induction of apoptosis in newly generated CTLs derived in vitro from spleen cells of Tg-RT-1 mice
To examine the induction of CTL apoptosis in vivo, we first confirmed whether apoptosis occurred in newly generated activated CTLs from Tg-RT-1 mice similar to the evidence previously obtained from the CD8 + HIV-1-IIIB gp160-specific CTL line (LINE-IIIB) (9) . Spleen cells from untreated Tg-RT-1 mice were restimulated in vitro with MMC-treated 15-12 cells (17) expressing gp160 protein of HIV-1-IIIB isolate for 4 days, and the obtained cells were confirmed as CD8β + P18-I10-specific CTLs (Fig. 1A) . Tg-RT-1-derived CTLs were then treated with various free peptides and induction of apoptosis was analyzed by flow cytometry as well as by DNA fragmentation. As shown in Fig. 1B and C, apoptosis induction in antigenspecific CTLs was detected by treatment with 1 µM epitope peptide, P18-I10 (RGPGRAFVTI) and its analog peptide I-10(325I) (RGPGRAFITI) (19), but not with control 10-mer peptide RF-10 (KGPGRVIYAT), an immunodominant site (aa 318-327) in gp160 derived from RF strain of HIV-1 (20) . Also, cytotoxic activity of CTLs was specifically decreased by treatment with peptide P18-I10 (Fig. 1D) .
Kinetics for the induction of antigen-specific CTLs in Tg-RT-1 mice after virus inoculation
We previously reported (23) Cytolytic activities of these virally activated CTLs were also determined. As shown in Fig. 2B , although a few H-2D d / P18-I10 pentamer-positive cells were detected in the spleen of uninfected mice, cytolytic activities were not detected in the splenic cells of Tg-RT-1 mice; however, when Tg-RT-1 mice were infected i.p. with 1 × 10 7 PFU of vSC25, strong cytolytic activities were observed even on day 1 and maintained for at least 3 days after inoculation.
Effect of peptide P18-I10 treatment in vivo on virusinoculated mice
We then examined the effect of free epitope peptide injection on antigen-specific activated CTLs in virus-inoculated Tg-RT-1 mice. One hundred micrograms of P18-I10 were injected intravenously (i.v.) into Tg-RT-1 mice 2 days after inoculation with vSC25. Spleen cells were obtained from untreated or peptide-treated mice 3 h after peptide injection and the percentage of antigen-specific CTLs was determined by flow cytometry. As shown in Fig. 3A and B, marked reduction in the percentage of CD8β + TCR-Vβ8 + cells and CD8β + H-2D d / P18-I10 pentamer-positive cells in spleen was observed by in vivo injection with peptide P18-I10. Cytolytic activities were also decreased in spleen cells of P18-I10-treated mice compared with untreated mice (Fig. 3C) . It is of note that in vivo injection of P18-I10 into uninfected normal Tg-RT-1 mice did not show any significant reduction in the percentage of splenic CD8β Cr-release assay using P18-I10-pulsed P815 cells as target cells. Cytolytic activities against unpulsed control P815 cells were always <5%. The results shown are representative of three independent experiments using two mice per group.
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not shown). These results indicated that a significant number of activated antigen-specific CD8 + CTLs was deleted by treatment with peptide P18-I10.
Treatment with peptide P18-I10 induces rapid onset of apoptosis in vivo
To examine whether the reduction in the percentage of antigen-specific CTLs in vivo by treatment with free epitope peptide injection was based on apoptosis, spleen cells from untreated or peptide-treated mice were stained with Annexin V. As shown in Thus, epitope peptide-induced apoptosis seems to be mediated through functional TCRs but not through complex formation between epitope peptide and class I MHC on activated CTLs (Fig. 4B) .
Time course studies demonstrated that the induction of apoptosis occurred predominantly on day 2 after vSC25 inoculation and was not detected on day 1 and day 3 Cr-release assay using P18-I10-pulsed P815 cells as target cells. The results shown are representative of three independent experiments using two mice per group. *P < 0.05. (Fig. 5A ). This may be because CTL apoptosis is likely to occur in the activating phase showing an increasing level of TCR expression but not in the activated state with a high expression of the TCR. This apoptosis also occurred when the inoculation dose of P18-I10 was as low as 4 µg per mouse (Fig. 5B) .
Morphological analyses of apoptosis induction in activated CTLs
To confirm the in vivo features of CTL apoptosis, we studied light microscopic and electron microscopic analyses using tissue sections from the spleen of P18-I10-treated mice. As shown in Fig. 6A and B, as compared with untreated Tg-RT-1 mice, a substantial number of dead cells strongly stained with toluidine blue was seen in spleen cells of P18-I10-treated Tg-RT-1 mice. Morphological changes by treatment with epitope peptide were also confirmed by electron microscopic analyses. Multiple cells with morphological features of apoptosis, such as chromatin condensation, were observed within sections of P18-I10-treated mice but not within untreated mice (Fig. 6C and D) . Phagocytes containing dead cells were also observed in the enlarged image of Fig. 6D indicated as a square (Fig. 6E) . These results clearly showed that apoptotic cell death was also induced in vivo by treatment with the epitope peptide. 
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Analysis of the mechanism of apoptosis in vivo
As shown above, CTL apoptosis in Tg-RT-1 mice treated with epitope peptide seems to be mediated through the TCR of activated CTLs by infection with vSC25. Indeed, it has been reported that TCR-mediated apoptosis was mainly Fas molecule-dependent and resulted in rapid upregulation of Fas ligand (FasL) on the cell surface following TCR ligation (24) . To analyze the mechanism of apoptosis in vivo, we examined the expression of cell surface molecules on apoptotic CTLs. As shown in Fig. 7A , the expression of early T-cell activation markers, such as CD69 and CD25, was apparently increased on antigen-specific CTLs from P18-I10-treated mice compared with untreated mice, and most CD69-stained activated cells were also positive for FasL. Furthermore, the expression of cell surface apoptosis-related molecules, Fas and FasL, was increased on CD8β + TCR-Vβ8 + CTLs in the apoptotic state (Fig. 7B ). These results suggested that apoptosis of CTLs in vivo was induced by cell-to-cell interaction, probably via the Fas-FasL-dependent pathway.
Recently, several reports have demonstrated that the level of immune-receptor programmed death-1 (PD-1) may primarily determine the apoptosis sensitivity of virus-specific CD8 + T cells and the expression level of PD-1 was significantly upregulated on exhausted CD8 + T cells during chronic viral infections (25) (26) (27) ; however, as far as 7 PFU of vSC25. At 1, 2 or 3 days after inoculation, mice were subsequently injected i.v. with 100 µg peptide P18-I10. At 3 h after injection of peptide, spleen cells were prepared from either control or peptide-treated mice and stained as in Fig. 4. (B) Tg-RT-1 mice were i.p. inoculated with 1 × 10 7 PFU of vSC25. Two days after inoculation, mice were subsequently treated with various concentrations of peptide P18-I10. At 3 h after injection of peptide, spleen cells were prepared from either control or peptide-treated mice and stained as in Fig. 4 . The results shown are representative of three independent experiments using two mice per group. *P < 0.05 and **P < 0.01. 7 PFU of vSC25. Two days after inoculation, mice were subsequently treated with 100 µg peptide P18-I10 (i.v.). Six hours after peptide injection, tissue sections were prepared from untreated or peptide-treated mice as described in Methods and stained with toluidine blue (A and B) . Sections of 100-nm thickness were cut using an ultramicrotome, grids were then counterstained with 2% uranyl acetate and 1% lead citrate and observed by electron microscope (C and D). (E) An enlarged image of the indicated portion of (D) is shown.
we have investigated, the expression of PD-1 as well as apoptosis-related molecule TNF-related apoptosis-inducing ligand (TRAIL) was not detected on H-2D d /P18-I10 pentamer-positive cells isolated from P18-I10-treated mice in our system (data not shown).
Effect of IL-2 addition on induction of apoptosis of CTLs
It has been reported that removal of IL-2 from activated T cells in vitro leads to reduced Bcl-2 expression and apoptosis, whereas addition of IL-2 prevents apoptosis of activated T cells by upregulation of Bcl-2 protein expression (28, 29) . 
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Therefore, we tried to examine the effect of IL-2 addition on induction of apoptosis of CTLs in our system. As shown in Fig. 8A , addition of 20 U ml −1 of recombinant IL-2 did not affect P18-I10-induced apoptosis in CTLs generated from spleen cells of Tg-RT-1 mice. Also, when vSC25-infected mice were pretreated with IL-2 before injection of peptide P18-I10, the percentage of H-2D d /P18-I10 pentamer-positive, Annexin V-positive apoptotic CTLs was not changed (Fig. 8B) . These results showed that addition of IL-2 could not rescue the induction of apoptosis of CTLs by free antigenic peptide in our in vivo system.
Treatment with either CsA or tacrolimus prevents the apoptosis of CTLs in vivo
CsA and tacrolimus are known to exert a selective inhibitory effect on T cells by binding with immunophilin, resulting in the inhibition of calcineurin catalytic activity. On the other hand, it has been reported that calcineurin induces apoptosis by suppressing the function of Bcl-2, and thus CsA and tacrolimus might have the capacity to inhibit apoptosis induction. Moreover, we have previously reported that pretreatment with CsA inhibits apoptosis induction in an activated CTL line in vitro (9) . On the basis of this finding, we examined the effect of CsA and tacrolimus on the induction of apoptosis on antigen-specific CTLs in vivo. We first examined their effect on the prevention of apoptosis in vitro using TCR-Vβ8 + CTLs generated from spleen cells of Tg-RT-1 mice. CsA significantly inhibited the apoptosis of activated CTLs treated with free antigenic peptide in vitro (Fig. 9A, left panel) . Moreover, partial inhibition was also observed by treatment with tacrolimus in vitro (Fig. 9A, right panel) .
We then examined the direct in vivo effect of CsA and tacrolimus on activated antigen-specific CTLs in vSC25-infected Tg-RT-1 mice. We have confirmed that two pretreatments with either CsA or tacrolimus did not affect the percentage of TCR-Vβ8 + CTLs (Fig. 9B ) and the percentage of apoptotic TCR-Vβ8 + CTLs determined by Annexin-V staining (Fig. 9C ). Under these conditions, when Tg-RT-1 mice were pretreated twice with CsA after vSC25 inoculation, induction of CTL apoptosis by epitope peptide P18-I10 was significantly inhibited when compared with CsA-untreated mice (Fig. 9D) . We then examined whether CTL apoptosis was inhibited by pretreatment with tacrolimus. Although tacrolimus did not inhibit apoptosis induction of the CTL line in vitro (9), apoptosis was markedly inhibited by preadministration with tacrolimus in an in vivo system (Fig. 9E) . Decrease of the cytolytic activities in spleen cells of P18-I10-treated mice also recovered by pretreatment with CsA or tacrolimus (Fig. 9F) .
These findings indicate that we can prevent the apoptosis of activated functional CTLs in vivo by pretreatments with CsA or tacrolimus.
Viral products containing epitope peptide seem to be released from 15-12 fibroblasts when attacked by specific CTLs
We have reported that viral products containing epitope peptide were released from 15-12 fibroblasts when they were treated with γ irradiation or with mild acid (30) . Here, we speculated that epitope peptide might be released from damaged or lyzed target cells and rapid apoptosis of CD8 + CTLs might be induced by the released epitope peptide in Cr-release assay using P18-I10-pulsed P815 cells as target cells. Cytolytic activities against unpulsed control P815 cells were always <5%. The results shown are representative of three independent experiments using three mice per group (B-F). *P < 0.05.
vivo. Therefore, we analyzed whether minimal epitope peptide, such as P18-I10 might be released from target cells during incubation with CTLs using bystander killing assay. As shown in Fig. 10 , when P18-I10-specific CTLs generated from spleen cells of Tg-RT-1 mice were incubated with 51 Cr-labeled Neo expressing D d -class I MHC that will capture P18-I10 in the presence of antigen-expressing 15-12 cells, bystander lysis of Neo targets was certainly observed. This finding indicates that epitope peptide might be released from infected targets when attacked by specific CTLs in vivo.
Discussion
In our previous study, we found that we could induce apoptosis in CD8 + HIV-1 envelope-specific murine CTLs by short exposure to antigenic peptide in vitro (9) . A number of reports have suggested that CD8 + CTL apoptosis may be elicited in vivo during the course of viral infection, particularly in the early phase of infection (31) (32) (33) (34) . However, most of the reports were performed using in vitro experimental systems with virus-specific CTL lines or clones (13, 14, 35) . Moreover, although Walden et al. (35) and Koniaras et al. (36) have shown that when ovalbumin (OVA) peptide was injected into either OVA-immunized mice or OVA-specific TCR Tg mice, respectively, apoptosis of OVA-specific CD8 + CTLs was detected in the spleen or in the thymus, they did not use virus-specific CD8 + CTLs.
We have reported previously that the inactivation of peptide-specific CTLs occurred in two conditions (9) : either when the CTL itself is exposed to free antigenic peptide or when the APCs present antigenic peptides at a very high density. However, those findings were obtained when we used recently stimulated established CTL lines in vitro but not in vivo. Here, we established unique Tg-RT-1 mice expressing α and β genes of TCRs of a CD8 + CTL clone, termed RT-1, specific to the immunodominant CTL epitope P18-I10 (RGPGRAFVTI) (15) . Using Tg-RT-1 mice, we tried to examine the possibility of CD8 + CTL apoptosis in vivo as well as to find a way to prevent CTL apoptosis in vivo for the development of a new strategy to inhibit persistent viral infection. In these Tg-RT-1 mice, we could see apoptosis of CD8 + CTLs in vivo only when they were activated by P18-I10-expressing vSC25 inoculation followed by epitope peptide P18-I10 administration. Such vSC25-activated CD8 + CTLs expressed early T-cell activation markers, such as CD69 and CD25, and the remaining activated CTLs more easily fell into apoptosis by repetitive epitope peptide injection (data not shown), suggesting that apoptosis might be induced repeatedly in vivo by viral products released from expanded viruses or virus-infected cells; therefore, in viral infections, it is better to maintain the activity of virus-specific CD8 + CTLs to suppress virus expansion and replication as early as possible. It should be noted that we could see apoptosis of CD8 + CTLs in vivo by epitope peptide inoculation only when they were activated by vSC25 administration but not by P18-I10 injection, suggesting that the actual mechanisms for CD8 + CTLs apoptosis induction in vivo may be distinct from those in vitro findings.
Santambrogio et al. showed that immature dendritic cells (DCs) secreted several proteases that acted extracellularly to process antigenic proteins into epitope peptides and that these peptides, which bound with class II MHC molecules on the surface of DCs, were presented to T cells (37, 38) . Similarly, we have reported that viral products containing epitope peptide were released from 15-12 fibroblasts when they were treated with γ irradiation or mild acid treatment (30) . We also found that minimally sized epitope peptide P18-I10 were generated extracellularly from P18IIIB and RP135, 15-mer and 25-mer peptides containing P18-I10, respectively, by serum proteases such as angiotensin-converting enzyme (39) . Moreover, we have seen the rapid apoptosis of CD8 + CTLs by epitope peptide-like substances released from 15-12 (our unpublished observation). These results suggest that minimal epitope peptide, such as P18-I10 would be generated from digested proteins or their fragments derived from viral infected cells or damaged cells. Thus, rapid apoptosis of CTLs might occur by virus-epitope-containing substances during infection, and such apoptosis of CTLs will permit the virus to persist.
Several mechanisms, such as single-cell self-destruction (suicide), peptide-induced CTL-CTL killing (fratricide), bystander killing and backward killing (40) , have been reported for epitope peptide-induced apoptosis on CD8 + CTLs. In our experiment, surface expression of both apoptosis-related molecules Fas and FasL was increased on spleen cells isolated from peptide-treated mice. These results suggested that Fas-mediated cell-to-cell interaction of CTLs with the same specificity was important for the induction of apoptosis. It has been widely accepted that antigen-specific CTLs play a central role in controlling viruses or tumors, and thus it is important to find a way to prevent the apoptosis of functional CTLs. In this article, we used CsA and tacrolimus to see whether the rapid apoptosis of CTLs with peptide was preventable by these immune modulators. Our previous in vitro study demonstrated that CsA but not tacrolimus inhibited apoptosis induction by exposure to epitope peptide P18-I10 in a specific CTL line (9); however, in the present study, we showed that both CsA and tacrolimus almost equally inhibited the apoptosis of CTLs in vivo ( Fig. 9D and E) . Although cell surface expression of FasL was not changed by peptide treatment on stimulated CTLs in vitro (9) , both Fas and FasL expression were increased in vivo via viral infections (Fig. 7) . It has been reported that TCR-induced upregulation of FasL expression on the cell surface was inhibited by both CsA and tacrolimus (41, 42) ; therefore, similar to CsA, apoptosis induction in vivo via viral infection can also be inhibited by tacrolimus by interfering with activation signals associated with FasL expression. Although CsA has been used as a therapeutic agent for many infectious diseases, such as HIV-1, its actual effect has remained controversial. Analysis of CsA-treated organ transplant recipients infected with HIV-1 shortly after transplantation (43) may provide reasonable information for explaining its role.
Recently, it has been shown that CsA inhibits HIV-1 infection by blocking the interaction between the HIV-1 capsid and target cell cyclophilin A, or the fusion of HIV-1 virions with susceptible target cells (44) ; however, Markowitz et al. reported that immunomodulation with CsA combined with antiretroviral therapy in early HIV-1 infection did not have apparent virologic or immunologic benefit compared with antiretroviral therapy alone (45) . Nevertheless, our current results suggest that immunosuppressive agents such as CsA or tacrolimus may be clinically useful to maintain functional CTLs by suppressing their apoptosis in acute viral infections. Analysis of the more precise mechanisms of apoptosis of antigen-specific CTLs demonstrated in this article will offer important information for the maintenance of functional CTLs in vivo and to control the persistence of viruses such as HIV-1.
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